Organizing Pneumonia and Pulmonary Eosinophilic Infiltration Associated with Daptomycin

Abstract

Development of new pulmonary infiltrates in patients treated with chronic daptomycin therapy should alert healthcare workers to this potential association.

Daptomycin-induced pulmonary infiltrates with eosinophilia

“…Drug-induced PIE typically manifests as areas of consolidation and ground-glass opacity on CT imaging commonly involving the outer third of the lungs. 2 Only two previous cases of PIE associated with daptomycin have been reported, but the possibility should be considered in patients receiving the drug who develop new pulmonary infiltrates. Our patient's presentation and findings suggest an adverse drug reaction to daptomycin.…”

Myopathy and Eosinophilic Pneumonia Coincidentally Induced by Treatment with Daptomycin

“…In order to clarify the clinical characteristics of DAP-induced EP, we performed a literature review. Consequently, the data for 25 previous cases and the present case are summarized in the Table (8,(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). The average age of the patients was 64 years (range: 26 to 87 years), and men were predominant (88%, 22 of 25 patients).…”

“…The exact pathophysiology of DAP-induced toxicity remains unknown; however, the accumulation of DAP in tissues is thought to be one pathogenic mechanism (8,11,17). It is well known that the long-term administration of DAP results in the recruitment of T-helper 2 lymphocytes and subsequent release of interleukin-5, which induces the migration of eosinophils (27), thereby causing cellular and/or epithelial damage (8,17,28). Therefore, it usually takes at least one week for pulmonary complications to appear.…”

A rare cause of pulmonary infiltrates one should be aware of: a case of daptomycin-induced acute eosinophilic pneumonia

“…In contrast, there are an increasing number of case reports about acute eosinophilic pneumonia secondary to daptomycin, which is a diagnosis of exclusion [5][6][7][8][9][10][11]. It is characterized by rapid onset (usually \7 days), fever, hypoxemia, bilateral pulmonary infiltrates, and eosinophilia (typically [25%) in bronchoalveolar lavage fluid or on lung biopsy.…”